Safety and Efficacy Study of Human ESC-derived Neural Precursor Cells in the Treatment of Parkinson's Disease

NCT03119636 ↗

Phase 1/2 Unknown 50 enrolled Chinese Academy of Sciences The First Affiliated Hospital of Zhengzhou University · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will evaluate the safety and efficacy of intracerebral transplantation of human embryonic stem cells-derived neural precursor cells in patients with Parkinson's Disease.

Timeline

Start: 2017-05
Primary completion: 2018-11
Completion: 2020-12

Publications

Wang YK, Zhu WW, Wu MH, Wu YH, Liu ZX, Liang LM, Sheng C, Hao J, Wang L, Li W, Zhou Q, Hu BY. Human Clinical-Grade Parthenogenetic ESC-Derived Dopaminergic Neurons Recover Locomotive Defects of Nonhuman Primate Models of Parkinson's Disease. Stem Cell Reports. 2018 Jul 10;11(1):171-182. doi: 10.1016/j.stemcr.2018.05.010. Epub 2018 Jun 14.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	neural precursor cells	Cell therapy	—	Other
Background	Levodopa	Small molecule	—	—

Safety and Efficacy Study of Human ESC-derived Neural Precursor Cells in the Treatment of Parkinson's Disease

Summary

Timeline

Publications

Drugs

Indications